INCOG BioPharma Services’ Post

“GLP-1 is projected to be a $100 billion market by 2030, indicating a substantial increase in syringe consumption.” says Cory Lewis, CEO, President, and Founder of INCOG BioPharma Services. Ahead of CDMO Live this week, Cory spoke to the PharmaSource podcast about why strategic thinking is crucial for success in this fast-moving landscape. 🎧 Listen to the full interview: https://lnkd.in/esj9YYAv “We’re not just planning for the immediate needs but looking one, two, even three years ahead. With our second and third production lines in the pipeline, we’re preparing for the long-term demands of the market.” Founded in June 2020, INCOG has secured FDA-approval and now establishes itself as a new force in contract manufacturing with a focus on sterile injectables. Despite the company only being four years old, INCOG’s leadership team brings decades of industry experience.  Cory says he has brought the ‘band back together’ by reuniting seasoned professionals to create a tier-one contract manufacturing organisation. INCOG’s investments in vial, syringe, and cartridge filling capabilities are “just the beginning” he says. “We’re also expanding into quality control, lab stability services, and eventually, auto-injector device assembly and final packaging. Our long-term site master plan outlines our ambition to not only enhance filling capacity, but also integrate additional business units to support commercial packaging and device assembly.” “Our first FDA approval, achieved less than eighteen months after production began, is a testament to our operational and quality excellence. This milestone was marked by an eight-day inspection with zero observations, a rare accomplishment in our industry.” --- Join INCOG at #CDMOLive this Thursday, for an exclusive online event dedicated to accelerating, optimising and decarbonising contract manufacturing. 👉 Register here for your free ticket: https://lnkd.in/eNB_vxzm #CDMO #GLP1

Points to consider for sterile filling and more! Agenda is published: https://lnkd.in/eeEjyk_U

E-Beam and X-Ray sterilization, with its superior penetration characteristics, processing flexibility, and regulatory acceptance, emerges as an advantageous method for terminal sterilization of dense drug products, providing a viable alternative to Gamma techniques in terms of efficiency, safety, and cost-effectiveness. Learn more from MediZap: https://ow.ly/yHNm50QJBpX

Did you know that the global syringes market is on the rise due to the surge in chronic diseases like diabetes and cancer? Sharps Technology, Inc. , a cutting-edge medical device company, is at the forefront of this healthcare transformation. Sharps specializes in smart safety syringe systems with FDA, WHO, and CE Mark approvals, ensuring safety for healthcare workers. They're developing prefilled syringe systems set to launch in Q4 2023, offering efficient drug delivery solutions. Sharps recently announced a 10-year purchase agreement with Nephrons Pharmaceuticals worth over $400 million! Invest in a company poised for triple-digit top-line growth and a path to profitability Sharps Technology is reshaping healthcare one syringe at a time. Watch the Investor Group Call Replay https://ow.ly/rygz50PTYyC Learn more about Sharps Technology and view disclosures: https://ow.ly/IpeO50PTYyE #HealthcareInnovation #MedicalDevices #InvestmentOpportunity #SharpsTechnology #SyringeRevolution

Interesting article by Riccardo Butta from Stevanato Group where he talks about GLP-1, the demand for this product and how he sees Stevanato Group preparing to meet the high demands for this and other high value solutions with their expansion in Italy and the US. Would love to hear other people's thoughts on this from within the market. #pharmaceutical #drugdelivery #glp-1 #pharma #pharmapackaging

Learn more on how Dow products can help with your formulation challenges #pharmaceuticals. Dow PEG benefits in different pharma formulations, #Topical Base, # Soft gel capsules, # Laxative etc.

🌟 Ensuring Excellence at Every Step! At Immacule & Acme Generics, we don't just meet standards; we set them. Our USFDA-approved facilities are a promise of partnership and quality for all your CDMO needs. 🔍 Experience our commitment to excellence. Let's discuss how we can support your pharmaceutical vision with precision and care. 📆 Meet us at DCAT—your vision deserves the best execution. #ImmaculeAcmeGenerics #DCAT2024 #PharmaCompliance #USFDA #CDMO #ExcellenceInExecution"

When it comes to unlocking the potential of your sterile injectable, we’ve got it down to an exact SI-ence 💉 As a leading global CDMO, we’re here to help unlock creative solutions to meet your project’s needs using our Pfizer lightspeed principles: 🔍 Identifying lead-time efficiencies  🤝 Flexibility in meeting your evolving expectations 🚧 Proactively overcoming roadblocks in supply Download the brochure below to discover how we’re dedicated to unlocking the potential of your sterile injectable. 🔓👇 https://lnkd.in/e7y9FVaq #LifeSciences #CDMO #DrugDevelopment #DrugManufacturing

Having the right balance of capacity and capabilities in all market conditions is the struggle that Contract Manufacturer Organizations face daily. Add to it the cost and complexity of maintaining a suitable parenteral manufacturing facility, the risks can be high. With constantly evolving parenteral market needs, having flexibility while achieving high utilization is key to long term success. To support these challenges, AST’s line of aseptic and syringe filling and closing machines provide adaptive fill-finish capabilities to ensure that any contract manufacturing organization has the right capabilities for any vial, syringe filling or cartridge application. Pharmaceutical Online, Joshua Russell, Joe Hoff #contractmanufacturing #asepticfilling #pharmaceuticalmanufacturing #celltherapymanufacturing #genetherapy

🌐 Navigating Regulatory Complexities with Precision! At Immacule & Acme Generics, our USFDA-approved production isn't just about compliance – it's about partnership, responsiveness, and unwavering commitment to your success. As an industry-leading CDMO, we dedicate ourselves to ensure not just delivery but excellence in every batch, exemplified by our pursuit of first-cycle approvals for your products. 🔬 Join us at DCAT to learn how we go the extra mile with our services in sterile and OSD production. We're here to reinforce your product pipeline with our stringent regulatory adherence, proactive customer service, and drive for perfect deliverables. 📅 Book a meeting at DCAT or get in touch to discuss how we can elevate your pharmaceutical products with our tried-and-true excellence. Immacule & Acme Generics – where your vision meets our meticulous execution. Viral Shah Pruthvish Soni Acme Generics #DCAT2024 #DCATWeek #PharmaCompliance #USFDAapproved #CDMO #SterileManufacturing #CMO #osd #sterile #CustomerExcellence #ServiceBeyondStandards